Skip to main content
SpringerLink
Log in

High-Dose-Rate Brachytherapy in the Treatment of Clinically Localized Prostate Cancer

  • Chapter
  • First Online:
Book cover Radiotherapy in Prostate Cancer

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

  • 1917 Accesses

Abstract

Recent radiobiological findings support that the α/β-ratio for prostate adenocarcinoma is less than that for the normal organs that ordinarily constrain the delivery of radiation therapy. As a result, hypofractionation has attracted greatly renewed interest and during the last 15 years a special interest in the implementation of brachytherapy (BRT) has evolved for the treatment of localized prostate cancer. Especially high-dose-rate (HDR) BRT is recently gaining momentum as an alternative to low-dose-rate and technological improvements in image guidance and real-time treatment planning place this interventional radiooncological modality at the forefront of innovation in radiotherapy. This chapter will explore the rationale for HDR BRT as a highly conformal method of dose delivery and safe biologic dose escalation through hypofractionation. Oncological outcome data and toxicity profiles will be discussed for the combination with external beam radiotherapy and in the monotherapy setting. In addition to clinical results of primary and salvage treatment protocols, dose-fractionation schedules and normal tissue dose constraints used by various centres are also reported.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Agoston P, Major T, Fröhlich G et al (2011) Moderate dose escalation with single-fraction high-dose-rate brachytherapy boost for clinically localized intermediate- and high-risk prostate cancer: 5-year outcome of the first 100 consecutively treated patients. Brachytherapy 10(5):376–384

    PubMed  Google Scholar 

  • Ahmed HU, Pendse D, Illing R et al (2007) Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol 4(11):632–642

    PubMed  Google Scholar 

  • Algan O, Jamgade A, Ali I et al (2012) The dosimetric impact of daily setup error on target volumes and surrounding normal tissue in the treatment of prostate cancer with intensity-modulated radiation therapy. Med Dosim 37(4):406–411

    PubMed  Google Scholar 

  • Aström L, Pedersen D, Mercke C et al (2005) Long-term outcome of high dose rate brachytherapy in radiotherapy of localized prostate cancer. Radiother Oncol 74(2):157–161

    PubMed  Google Scholar 

  • Aydin H, Tsuzuki T, Hernandez D et al (2004) Positive proximal (bladder neck) margin at radical prostatectomy confers greater risk of biochemical progression. Urology 64(3):551–555

    PubMed  Google Scholar 

  • Barkati M, Williams SG, Foroudi F et al (2012) High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a phase II trial. Int J Radiat Oncol Biol Phys 82(5):1889–1896

    PubMed  Google Scholar 

  • Battermann JJ, Boon TA, Moerland MA (2004) Results of permanent prostate brachytherapy, 13 years of experience at a single institution. Radiother Oncol 71(1):23–28

    PubMed  Google Scholar 

  • Bolla M, Poppel HV (2012) Management of prostate cancer. A multidisciplinary approach. Springer, Berlin

    Google Scholar 

  • Brachman DG, Thomas T, Hilbe J et al (2000) Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2,222 patients: results from a single practice. Int J Radiat Oncol Biol Phys 48(1):111–117

    CAS  PubMed  Google Scholar 

  • Brenner DJ (2004) Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys 60(4):1013–1015

    PubMed  Google Scholar 

  • Brenner DJ, Hall EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43(5):1095–1101

    CAS  PubMed  Google Scholar 

  • Brenner DJ, Martinez AA, Edmundson GK et al (2002) Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52(1):6–13

    PubMed  Google Scholar 

  • Briganti A, Blute ML, Eastham JH et al (2009) Pelvic lymph node dissection in prostate cancer. Eur Urol 55(6):1251–1265

    PubMed  Google Scholar 

  • Bruce JY, Lang JM, McNeel DG et al (2012) Current controversies in the management of biochemical failure in prostate cancer. Clin Adv Hematol Oncol 10(11):716–722

    PubMed  Google Scholar 

  • Chen CP, Weinberg V, Shinohara K et al (2013) Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys 86(2):324–329

    PubMed  Google Scholar 

  • Chuang A, Nielsen ME, Hernandez DJ et al (2007) The significance of positive surgical margin in areas of capsular incision in otherwise organ-confined disease at radical prostatectomy. J Urol 178:1306–1310

    PubMed  Google Scholar 

  • Coen JJ, Zietman AL, Thakral H et al (2002) Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol 20(15):3199–3205

    PubMed  Google Scholar 

  • Corner C, Rojas AM, Bryant L et al (2008) A Phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 72(2):441–446

    PubMed  Google Scholar 

  • D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974

    PubMed  Google Scholar 

  • D’Amico AV, Whittington R, Malkowicz SB et al (2002) Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95(2):281–286

    PubMed  Google Scholar 

  • Davis BJ, Pisansky TM, Wilson TM et al (1999) The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer 85(12):2630–2637

    CAS  PubMed  Google Scholar 

  • de Meerleer G, Vakaet L, Meersschout S et al (2004) Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys 60(3):777–787

    PubMed  Google Scholar 

  • Dearnaley DP, Sydes MR, Graham JD et al (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8(6):475–487

    PubMed  Google Scholar 

  • Deger S, Boehmer D, Roigas J et al (2005) High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. Eur Urol 47(4):441–448

    PubMed  Google Scholar 

  • Demanes DJ, Rodriguez RR, Schour L et al (2005) High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: california endocurietherapy’s 10-year results. Int J Radiat Oncol Biol Phys 61(5):1306–1316

    PubMed  Google Scholar 

  • Demanes DJ, Brandt D, Schour L et al (2009) Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Am J Clin Oncol 32(4):342–347

    PubMed  Google Scholar 

  • Demanes DJ, Martinez AA, Ghilezan M et al (2011) High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 81(5):1286–1292

    PubMed  Google Scholar 

  • Deutsch I, Zelefsky MJ, Zhang Z et al (2010) Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. Brachytherapy 9(4):313–318

    PubMed  Google Scholar 

  • Djavan B, Moul JW, Zlotta A et al (2003) PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. Eur Urol 43(1):12–27

    PubMed  Google Scholar 

  • Eid K, Krughoff K, Stoimenova D et al (2013) Validation of the urgency, weak stream, incomplete emptying, and nocturia (uwin) score compared with the american urological association symptoms score in assessing lower urinary tract symptoms in the clinical setting. Urology. 83(1):181–185

    PubMed  Google Scholar 

  • Evangelista L, Guttilla A, Zattoni F et al (2013) Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 63(6):1040–1048

    PubMed  Google Scholar 

  • Fatyga M, Williamson JF, Dogan N et al (2009) A comparison of HDR brachytherapy and IMRT techniques for dose escalation in prostate cancer: a radiobiological modeling study. Med Phys 36(9):3995–4006

    CAS  PubMed Central  PubMed  Google Scholar 

  • Fowler J, Chappell R, Ritter M (2001) Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50(4):1021–1031

    CAS  PubMed  Google Scholar 

  • Franca CAS, Vieira SL, Carvalho ACP, et al (2009) Radioactive seed migration after prostate brachytherapy with iodine-125 using loose seeds versus stranded seeds. Int Braz J Urol 35(5):573–579 (discussion 579–580)

    Google Scholar 

  • Galalae RM, Kovács G, Schultze J et al (2002) Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 52(1):81–90

    PubMed  Google Scholar 

  • Galalae RM, Martinez A, Mate T et al (2004) Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 58(4):1048–1055

    PubMed  Google Scholar 

  • Galalae RM, Martinez A, Nuernberg N et al (2006) Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups? Strahlenther Onkol 182(3):135–141

    PubMed  Google Scholar 

  • Ghadjar P, Keller T, Rentsch CA et al (2009) Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. Brachytherapy 8(1):45–51

    PubMed  Google Scholar 

  • Ghilezan M, Martinez A, Gustason G et al (2011) High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: preliminary toxicity data. Int J Radiat Oncol Biol Phys 83(3):927–932

    PubMed  Google Scholar 

  • Grills IS, Martinez AA, Hollander M et al (2004) High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. The Journal of Urology 171(3):1098–1104

    PubMed  Google Scholar 

  • Grimm P, Billiet I, Bostwick D et al (2012) Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. results from the prostate cancer results study group. BJU Int. 109(Suppl 1):22–29

    PubMed  Google Scholar 

  • Han M, Partin AW, Pound CR et al (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28(3):555–565

    CAS  PubMed  Google Scholar 

  • Han M, Partin AW, Zahurak M et al (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169(2):517–523

    PubMed  Google Scholar 

  • Hanks GE, Hanlon AL, Pinover WH et al (2000) Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 46(4):823–832

    CAS  PubMed  Google Scholar 

  • Hanks GE, Hanlon AL, Horwitz EM (2001) Evidence for cure of ‘young’ men with prostate cancer. Oncology (Williston Park, N.Y.) 15(5):563–567 (discussion 571–574)

    Google Scholar 

  • Harlan LC, Potosky A, Gilliland FD et al (2001) Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. JNCI Journal of the National Cancer Institute 93(24):1864–1871

    CAS  Google Scholar 

  • Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localized disease. Eur Urol 59(1):61–71

    PubMed  Google Scholar 

  • Hiratsuka J, Jo Y, Yoshida K et al (2004) Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Int J Radiat Oncol Biol Phys 59(3):684–690

    PubMed  Google Scholar 

  • Holly R, Morton GC, Sankreacha R et al (2011) Use of cone-beam imaging to correct for catheter displacement in high dose-rate prostate brachytherapy. Brachytherapy 10(4):299–305

    PubMed  Google Scholar 

  • Hoskin P (2008) High dose rate brachytherapy for prostate cancer. Cancer Radiother 12(6–7):512–514

    CAS  PubMed  Google Scholar 

  • Hoskin PJ, Motohashi K, Bownes P et al (2007) High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol 84(2):114–120

    PubMed  Google Scholar 

  • Hoskin P, Rojas A, Lowe G et al (2012) High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence. Int J Radiat Oncol Biol Phys 82(4):1376–1384

    PubMed  Google Scholar 

  • Hoskin PJ, Colombo A, Henry A et al (2013) GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localized prostate cancer: an update. Radiother Oncol 107(3):325–332

    PubMed  Google Scholar 

  • Ishiyama H, Hirayama T, Jhaveri P, et al (2012) Is there an increase in genitourinary toxicity in patients treated with transurethral resection of the prostate and radiotherapy?: A systematic review. Am J Clin Oncol 37(3):297–304

    Google Scholar 

  • Izard MA, Haddad RL, Fogarty GB et al (2006) Six year experience of external beam radiotherapy, brachytherapy boost with a 1 Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer. Int J Radiat Oncol Biol Phys 66(1):38–47

    PubMed  Google Scholar 

  • Karabis A, Giannouli S, Baltas D (2005) HIPO: A hybrid inverse treatment planning optimization algorithm in HDR brachytherapy. Radiother Oncol 76(Suppl. 2):29

    Google Scholar 

  • Kim MM, Hoffman KE, Levy LB et al (2012) Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease? Eur J Cancer 48(11):1664–1671

    PubMed  Google Scholar 

  • Knaup C, Mavroidis P, Esquivel C et al (2012) Investigating the dosimetric and tumor control consequences of prostate seed loss and migration. Med Phys 39(6):3291–3298

    PubMed Central  PubMed  Google Scholar 

  • Komiya A, Fujiuchi Y, Ito T et al (2013) Early quality of life outcomes in patients with prostate cancer managed by high-dose-rate brachytherapy as monotherapy. Int J Urol 20(2):185–192

    CAS  PubMed  Google Scholar 

  • Kono Y, Kubota K, Aruga T et al (2010) Swelling of the prostate gland by permanent brachytherapy may affect seed migration. Jpn J Clin Oncol 40(12):1159–1165

    PubMed  Google Scholar 

  • Kotecha R, Yamada Y, Pei X et al (2013) Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer. Brachytherapy 12(1):44–49

    PubMed  Google Scholar 

  • Krauss D, Kestin L, Ye H et al (2011) Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol Phys 80(4):1064–1071

    PubMed  Google Scholar 

  • Kuban D, Tucker S, Dong L et al (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67–74

    PubMed  Google Scholar 

  • Kupelian P, Meyer JL (2011) Image-guided, adaptive radiotherapy of prostate cancer: toward new standards of radiotherapy practice. Front Radiat Ther Oncol 43:344–368

    PubMed  Google Scholar 

  • Kupelian PA, Ciezki J, Reddy CA et al (2008) Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 71(1):16–22

    PubMed  Google Scholar 

  • Lakosi F, Antal G, Vandulek C et al (2011) Open MR-guided high-dose-rate (HDR) prostate brachytherapy: feasibility and initial experiences open MR-guided high-dose-rate (HDR) prostate brachytherapy. Pathol. Oncol. Res. 17(2):315–324

    PubMed  Google Scholar 

  • Le H, Rojas A, Alonzi R et al (2013) The influence of prostate volume on outcome after high-dose-rate brachytherapy alone for localized prostate cancer. Int J Radiat Oncol Biol Phys 87(2):270–274

    PubMed  Google Scholar 

  • Lee WR (2009) Extreme hypofractionation for prostate cancer. Expert Rev Anticancer Ther 9(1):61–65

    CAS  PubMed  Google Scholar 

  • Lee B, Shinohara K, Weinberg V et al (2007) Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 67(4):1106–1112

    PubMed  Google Scholar 

  • Luo HL, Fang FM, Chuang YC et al (2009) Previous transurethral resection of the prostate is not a contraindication to high-dose rate brachytherapy for prostate cancer. BJU Int 104(11):1620–1623

    PubMed  Google Scholar 

  • Luo HL, Fang FM, Kang CH et al (2013) Can high-dose-rate brachytherapy prevent the major genitourinary complication better than external beam radiation alone for patients with previous transurethral resection of prostate? Int Urol Nephrol 45(1):113–119

    PubMed  Google Scholar 

  • Mark R, Anderson P, Akins R (2010) Interstitial high-dose-rate brachytherapy as monotherapy for early stage prostate cancer: median 8-year results in 301 patients (Abstract). Brachytherapy 9:76

    Google Scholar 

  • Martin T, Baltas D, Kurek R et al (2004a) 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study. Strahlenther Onkol 180(4):225–232

    PubMed  Google Scholar 

  • Martin T, Röddiger S, Kurek R et al (2004b) 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer. Radiother Oncol 71(1):35–41

    PubMed  Google Scholar 

  • Martinez AA, Pataki I, Edmundson G et al (2001) Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys 49(1):61–69

    CAS  PubMed  Google Scholar 

  • Martinez AA, Gustafson G, Gonzalez J et al (2002) Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 53(2):316–327

    PubMed  Google Scholar 

  • Martinez A, Gonzalez J, Spencer W, et al (2003) Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J. Urol. 169(3):974–979 (discussion 979–980)

    Google Scholar 

  • Martinez A, Galalae R, Gonzalez J et al (2003b) No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose. J Urol 170:2296–2301

    PubMed  Google Scholar 

  • Martinez AA, Demanes DJ, Galalae R et al (2005) Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated-hypofractionated regime. Int J Radiat Oncol Biol Phys 62(5):1322–1331

    PubMed  Google Scholar 

  • Martinez AA, Demanes J, Vargas C et al (2010) High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 33(5):481–488

    PubMed  Google Scholar 

  • Martinez AA, Gonzalez J, Ye H et al (2011) Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 79(2):363–370

    PubMed  Google Scholar 

  • Masson S, Persad R, Bahl A (2012) HDR Brachytherapy in the Management of High-Risk Prostate Cancer. Adv Urol 2012:980841

    PubMed Central  PubMed  Google Scholar 

  • Mavroidis P, Katsilieri Z, Kefala V et al (2010) Radiobiological evaluation of the influence of dwell time modulation restriction in HIPO optimized HDR prostate brachytherapy implants. J Contemp Brachyther 2(3):117–128

    Google Scholar 

  • Ménard C, Susil RC, Choyke P et al (2004) MRI-guided HDR prostate brachytherapy in standard 1.5T scanner. Int J Radiat Oncol Biol Phys 59(5):1414–1423

    PubMed Central  PubMed  Google Scholar 

  • Milickovic N, Mavroidis P, Tselis N et al (2011) 4D analysis of influence of patient movement and anatomy alteration on the quality of 3D U/S-based prostate HDR brachytherapy treatment delivery. Med Phys 38(9):4982–4993

    PubMed  Google Scholar 

  • Miralbell R, Roberts SA, Zubizarreta E et al (2012) Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys 82(1):17–24

    Google Scholar 

  • Mohler J, Bahnson RR, Boston B et al (2010) NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 8(2):162–200

    CAS  PubMed  Google Scholar 

  • Monroe AT, Faricy PO, Jennings SB et al (2008) High-dose-rate brachytherapy for large prostate volumes (≥50 cc)—Uncompromised dosimetric coverage and acceptable toxicity. Brachytherapy 7(1):7–11

    PubMed  Google Scholar 

  • Morton GC, Loblaw DA, Sankreacha R et al (2010) Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life. Int J Radiat Oncol Biol Phys 77(3):811–817

    PubMed  Google Scholar 

  • Mutanga TF, de Boer HCJ, Rajan V et al (2012) Day-to-day reproducibility of prostate intrafraction motion assessed by multiple kV and MV imaging of implanted markers during treatment. Int J Radiat Oncol Biol Phys 83(1):400–407

    PubMed  Google Scholar 

  • Nag S, Dobelbower R, Glasgow G et al (2003) Inter-society standards for the performance of brachytherapy: a joint report from ABS, ACMP and ACRO. Crit Rev Oncol Hematol 48(1):1–17

    PubMed  Google Scholar 

  • Nath R, Bice WS, Butler WM et al (2009) AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: report of Task Group 137. Med Phys 36(11):5310–5322

    CAS  PubMed Central  PubMed  Google Scholar 

  • Nguyen PL, Chen M, D’Amico AV et al (2007) Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer 110(7):1485–1492

    PubMed  Google Scholar 

  • Nguyen Q, Levy LB, Lee AK et al (2013) Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer 119(18):3265–3271

    CAS  PubMed  Google Scholar 

  • Noda Y, Sato M, Shirai S et al (2011) Efficacy and safety of high-dose-rate brachytherapy of single implant with two fractions combined with external beam radiotherapy for hormone-naïve localized prostate cancer. Cancers (Basel) 3(3):3585–3600

    Google Scholar 

  • Oliai C, Yang L, Lee JY (2013) Prospective quality of life and efficacy of high-dose-rate brachytherapy salvage for recurrent prostate cancer. Int J Radiat Oncol Biol Phys 87(2):396

    Google Scholar 

  • Pahlajani N, Ruth KJ, Buyyounouski MK et al (2012) Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer. Int J Radiat Oncol Biol Phys 82(5):1949–1956

    PubMed  Google Scholar 

  • Peddada AV, Jennings SB, Faricy PO et al (2007) Low morbidity following high dose rate brachytherapy in the setting of prior transurethral prostate resection. J Urol 178(5):1963–1967

    PubMed  Google Scholar 

  • Peeters STH, Heemsbergen WD, Koper PCM et al (2006) Dose-response in radiotherapy for localized prostate cancer: results of the dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24(13):1990–1996

    PubMed  Google Scholar 

  • Pellizzon ACA, Salvajoli J, Novaes P et al (2008) The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition. Int J Med Sci 5(3):113–120

    PubMed Central  PubMed  Google Scholar 

  • Pellizzon A, Miziara MC. Neviani C (2009) Long-term results of salvage interstitial high-dose brachytherapy for local-only recurrent prostate cancer treated with definitive conventional external beam radiotherapy. http://meetinglibrary.asco.org/content/20049-64

  • Phan TP, Syed AMN, Puthawala A, et al (2007) High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. J Urol 177(1):123–127 (discussion 127)

    Google Scholar 

  • Pistis F, Guedea F, Pera J et al (2010) External beam radiotherapy plus high-dose-rate brachytherapy for treatment of locally advanced prostate cancer: the initial experience of the Catalan Institute of Oncology. Brachytherapy 9(1):15–22

    PubMed  Google Scholar 

  • Pollack A, Zagars GK, Starkschall G et al (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53(5):1097–1105

    PubMed  Google Scholar 

  • Potters L, Morgenstern C, Calugaru E et al (2005) Twelve-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173(5):1562–1566

    PubMed  Google Scholar 

  • Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281(17):1591–1597

    CAS  PubMed  Google Scholar 

  • Prada PJ, Mendez L, Fernández J et al (2012a) Long-term biochemical results after high-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for high risk prostate cancer. Radiat Oncol 7:31

    PubMed Central  PubMed  Google Scholar 

  • Prada PJ, Jimenez I, González-Suárez H et al (2012b) High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results. Brachytherapy 11(2):105–110

    PubMed  Google Scholar 

  • Ritter M, Forman J, Kupelian P et al (2009) Hypofractionation for prostate cancer. Cancer J 15(1):1–6

    PubMed Central  PubMed  Google Scholar 

  • Rogers CL, Alder SC, Rogers RL et al (2012) High dose brachytherapy as monotherapy for intermediate-risk prostate cancer. J Urol 187(1):109–116

    PubMed  Google Scholar 

  • Sakamoto N, Akitake M, Ikoma S et al (2011) Clinical outcome in prostate cancer patients undergoing high-dose-rate brachytherapy with external beam radiotherapy in our institute. Nippon Hinyokika Gakkai Zasshi 102(4):621–627

    PubMed  Google Scholar 

  • Sathya JR, Davis IR, Julian JA et al (2005) Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23(6):1192–1199

    PubMed  Google Scholar 

  • Scala L, Page PN, Lee JW (2009) Salvage high dose rate brachytherapy for locally recurrent prostate cancer after primary radiotherapy. Int J Radiat Oncol Biol Phys 75(3):322

    Google Scholar 

  • Seppenwoolde Y, Kolkman-Deurloo I, Sipkema D et al (2008) HDR prostate monotherapy: dosimetric effects of implant deformation due to posture change between TRUS- and CT-imaging. Radiother Oncol 86(1):114–119

    PubMed  Google Scholar 

  • Shah AP, Kupelian PA, Willoughby TR et al (2011) An evaluation of intrafraction motion of the prostate in the prone and supine positions using electromagnetic tracking. Radiother Oncol 99(1):37–43

    PubMed  Google Scholar 

  • Stone NN, Potters L, Davis BJ et al (2007) Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys 69(5):1472–1477

    PubMed  Google Scholar 

  • Stone NN, Stock RG, Cesaretti JA et al (2010) Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys 76(2):355–360

    PubMed  Google Scholar 

  • Sung M, Lin H, Koch MO et al (2007) Radial distance of extraprostatic extension measured by ocular micrometer is an independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of pT3a prostate cancer. Am J Surg Pathol 31(2):311–318

    PubMed  Google Scholar 

  • Touijer K, Fuenzalida RP, Rabbani F et al (2011) Extending the indications and anatomical limits of pelvic lymph node dissection for prostate cancer: improved staging or increased morbidity? BJU Int 108(3):372–377

    PubMed  Google Scholar 

  • Tselis N, Tunn UW, Chatzikonstantinou G et al (2013) High dose rate brachytherapy as monotherapy for localized prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients. Radiat Oncol 8:115

    PubMed Central  PubMed  Google Scholar 

  • Tucker SL, Thames HD, Michalski JM et al (2011) Estimation of α/β for late rectal toxicity based on RTOG 94–06. Int J Radiat Oncol Biol Phys 81(2):600–605

    PubMed Central  PubMed  Google Scholar 

  • Vargas CE, Martinez AA, Boike TP et al (2006) High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study. Int J Radiat Oncol Biol Phys 66(2):416–423

    PubMed  Google Scholar 

  • Viani GA, Pellizzon AC, Guimarães FS et al (2009) High dose rate and external beam radiotherapy in locally advanced prostate cancer. Am J Clin Oncol 32(2):187–190

    PubMed  Google Scholar 

  • Ward JF, Sebo TJ, Blute ML et al (2005) Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol 173(4):1156–1160

    PubMed  Google Scholar 

  • Ward JF, Pagliaro LC, Pisters LL (2008) Salvage therapy for radiorecurrent prostate cancer. Curr Probl Cancer 32(6):242–271

    PubMed  Google Scholar 

  • Whitaker M, Hruby G, Lovett A et al (2011) Prostate HDR brachytherapy catheter displacement between planning and treatment delivery. Radiother Oncol 101(3):490–494

    PubMed  Google Scholar 

  • White EC, Kamrava MR, Demarco J et al (2013) High-dose-rate prostate brachytherapy consistently results in high quality dosimetry. Int J Radiat Oncol Biol Phys 85(2):543–548

    PubMed  Google Scholar 

  • Yamada Y, Rogers L, Demanes DJ et al (2012) American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 11(1):20–32

    PubMed  Google Scholar 

  • Yoshioka Y, Konishi K, Sumida I et al (2011) Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions. Int J Radiat Oncol Biol Phys 80(2):469–475

    PubMed  Google Scholar 

  • Yoshioka Y, Yoshida K, Yamazaki H et al (2013a) The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer. J Radiat Res 54(5):781–788

    PubMed Central  PubMed  Google Scholar 

  • Yoshioka Y, Konishi K, Suzuki O et al (2013b) Monotherapeutic high-dose-rate brachytherapy for prostate cancer: a dose reduction trial. Radiother Oncol 110(1):114–119

    PubMed  Google Scholar 

  • Zamboglou N, Tselis N, Baltas D, et al (2012) High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. Int J Radiat Oncol Biol Phys 85(3):672–678

    Google Scholar 

  • Zaorsky NG, Doyle LA, Yamoah K et al (2013) High dose rate brachytherapy boost for prostate cancer: A systematic review. Cancer Treat Rev 40(3):414–425

    PubMed  Google Scholar 

  • Zelefsky MJ, Leibel SA, Gaudin PB et al (1998) Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41(3):491–500

    CAS  PubMed  Google Scholar 

  • Zelefsky MJ, Kuban DA, Levy LB et al (2007a) Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67(2):327–333

    PubMed  Google Scholar 

  • Zelefsky MJ, Kattan MW, Fearn P et al (2007b) Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Urology 70(2):283–287

    PubMed  Google Scholar 

  • Zelefsky MJ, Yamada Y, Fuks Z et al (2008a) Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 71(4):1028–1033

    PubMed  Google Scholar 

  • Zelefsky MJ, Reuter VE, Fuks Z, et al (2008b) Influence of local tumor control on distant metastases and cancer-related mortality after external beam radiotherapy for prostate cancer. J. Urol. 179(4):1368–1373 (discussion 1373)

    Google Scholar 

  • Zelefsky MJ, Pei X, Chou JF et al (2011) Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 60(6):1133–1139

    PubMed  Google Scholar 

  • Zietman AL, Bae K, Slater JD et al (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 28(7):1106–1111

    PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sana Klinikum Offenbach Strahlenklinik, 63069, Offenbach, Germany

    Nikolaos Tselis & Nikolaos Zamboglou

Authors
  1. Nikolaos Tselis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nikolaos Zamboglou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nikolaos Tselis .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Krankenhaus der Barmherzigen, Schwestern Linz, Johannes Kepler University, Linz, Austria

    Hans Geinitz

  2. University of California, San Francisco Department of Radiation Oncology, San Francisco, California, USA

    Mack Roach III

  3. The Institute of Cancer Research Sutton, Sutton Surrey, United Kingdom

    Nicholas van As

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Tselis, N., Zamboglou, N. (2014). High-Dose-Rate Brachytherapy in the Treatment of Clinically Localized Prostate Cancer. In: Geinitz, H., Roach III, M., van As, N. (eds) Radiotherapy in Prostate Cancer. Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/174_2014_1020

Download citation

  • DOI: https://doi.org/10.1007/174_2014_1020

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-37098-4

  • Online ISBN: 978-3-642-37099-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation